472. Deputy Mattie McGrath asked the Minister for Health if a reason has been established as to the reason there was a delay in notifying Irish users of sodium valproate, known as Epilim, regarding risks associated with its use; the reason information on the risks to pregnant women was first included in UK in 2002 but the same information did not appear here until 2008 (details supplied); and if he will make a statement on the matter. [25479/19]

Summary

472. Deputy Mattie McGrath asked the Minister for Health if a reason has been established as to the reason there was a delay in notifying Irish users of sodium valproate, known as Epilim, regarding risks associated with its use; the reason information on the risks to pregnant women was first included in UK in 2002 but the same information did not appear here until 2008 (details supplied); and if he will make a statement on the matter. [25479/19]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 18 June 2019

   Health Products Regulatory Authority

   472. Deputy Mattie McGrath asked the Minister for Health if a reason has been established as to the reason there was a delay in notifying Irish users of sodium valproate, known as Epilim, regarding risks associated with its use; the reason information on the risks to pregnant women was first included in UK in 2002 but the same information did not appear here until 2008 (details supplied); and if he will make a statement on the matter. [25479/19]

   Source: written

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Health Products Regulatory Authority

  xml · EN · 18 June 2019

  ViewDownloadOpen at official source

Sponsors

• McGrath, Mattie. · Asking member
• Health · Health · Addressed to

Related records

No cross-record relationships stored yet.